Examples of using Dmards in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Approximately 20% of patients had received prior treatment with DMARDs other than MTX.
DMARDs may be prescribed for ankylosing spondylitis but benefit those with involvement of peripheral joints such as knees, hips, shoulders, ankles and wrists.
Notably, some blood pressure medicines and DMARDs can harm the development of the foetus.
Decreases below 0.5 x 109/ l were reported in 0.3%patients receiving tocilizumab 8 mg/kg plus DMARDs.
Patients previously treated with DMARDs or biologics who received apremilast achieved a greater ACR 20 response at Week 16 than patients receiving placebo.
Cimzia was also compared with placebo in 879 adults with active rheumatoidarthritis who had never received treatment with DMARDs.
No dose adjustment isrequired when used in combination with other DMARDs, corticosteroids, salicylates, nonsteroidal anti-inflammatory drugs(NSAIDs), or analgesics.
Summary of ADRs occurring in patientswith RA receiving tocilizumab as monotherapy or in combination with MTX or other DMARDs.
For adults with psoriatic arthritis who have not responded well to DMARDs the CHMP noted the limited treatments available and considered that Stelara would be of benefit in these patients.
Responses observed in the apremilast treated group were similar in patients receiving andnot receiving concomitant DMARDs, including MTX.
Consistent efficacy was seen in patients regardless of use of DMARDs(MTX, sulfasalazine and/or hydroxychloroquine), HLA-B27 antigen status or baseline CRP levels as assessed by ASAS 20 responses at week 14.
In SC- II, 656 patients were randomized 2:1 to tocilizumab subcutaneous 162 mg every other week or placebo,in combination with non-biologic DMARDs.
A total of 76.4% of patients were previously treated with only small-molecule DMARDs and 22.4% of patients were previously treated with biologic DMARDs, which includes 7.8% who had a therapeutic failure with a prior biologic DMARD.
Cimzia can also be given alone when treatment with methotrexate is not appropriate. severe, active and progressive rheumatoid arthritis that hasnot been previously treated with methotrexate or other DMARDs.
For active rheumatoid arthritis that hasnot responded adequately to previous treatment with DMARDs, Cimzia has been compared with placebo(a dummy treatment) in two main studies involving 1,601 adults who were receiving methotrexate treatment.
In the 6-month controlled trials decreases in platelet counts below 100 x 103/ μl occurred in 1.7% of patients on tocilizumab 8 mg/kg plus DMARDs compared to< 1% on placebo plus DMARDs.
In controlled clinical studies, the rate of seriousinfections with tocilizumab 8 mg/ kg plus DMARDs was 5.3 events per 100 patient years exposure compared to 3.9 events per 100 patient years exposure in the placebo plus DMARD group.
In Study III the efficacy and safety of abatacept were assessed in patients with an inadequate response to a TNF-inhibitor, with the TNF-inhibitor discontinued prior to randomization;other DMARDs were permitted.
The most commonly reported ADRs(occurring in≥ 5% of patients treated with tocilizumab monotherapy orin combination with DMARDs) were upper respiratory tract infections, nasopharyngitis, headache, hypertension and increased ALT.
It is used in combination with another medicine, methotrexate, when the disease has not respondedadequately to other treatments called disease-modifying antirheumatic drugs(DMARDs), including methotrexate.
In the last study inpatients who had never received treatment with DMARDs, almost 29% of patients(189 out of 655) treated with Cimzia in combination with methotrexate were in sustained remission after 52 weeks of treatment, compared with 15%(32 out of 213) of patients receiving placebo with methotrexate.
In the 6-month controlled trials decreases in neutrophil counts below 1 x 109/ l occurred in 3.4% of patients on tocilizumab 8 mg/kg plus DMARDs compared to< 0.1% of patients on placebo plus DMARDs.
Since end 2005/early 2006, patient recruitment is ongoing in the MabThera phase III programme for patients whohave had an inadequate response or who are intolerant to treatment with one or more disease-modifying antirheumatic drugs(DMARDs).
Second multinational phase III study provides further evidence of the significant role of IL-6 receptor inhibition in the treatment of rheumatoid arthritisRoche announced today that TOWARD1, the second multinational phase III Actemra(tocilizumab) study, successfully reached its primary endpoint and showed that a greater proportion of patients treated with Actemra in combination with traditional disease modifying drugs(DMARDs) achieved a significant improvement in disease signs and symptoms at week 24, compared to the those treated with DMARDs alone.
On December 3, the Swiss authorities approved Ro Actemra for the treatment of moderately severe to severe, active rheumatoid arthritis in adult patients whodid not respond adequately to treatment with DMARDs or tumor necrosis factor(TNF) inhibitors.
ORENCIA in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis(JIA) in paediatric patients 6 years of age andolder who have had an insufficient response to other DMARDs including at least one TNF inhibitor.
During the 6-month controlled trials transient elevations in ALT/AST> 3 x ULN were observed in 2.1% of patients on tocilizumab 8 mg/kg compared to 4.9% of patients on MTX and in 6.5% of patients who received 8 mg/kg tocilizumab plus DMARDs compared to 1.5% of patients on placebo plus DMARDs.